{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Section(s)', 'Description of Change', 'Rationale for the Change', 'Section 13.2.1.1: Interim', \"To compare the ORR ( PR) based on the IRC's\", 'events have occurred, regardless of', 'Analysis of PFS for Sample Size', 'response outcome assessments (Section 6.4), in', 'association with accrual status.', 'Re-estimation', 'patients randomized to the SVd Arm versus the', '5) The definition of ORR was revised to align', 'Section 13.2.1.2: Interim', 'Vd Arm', 'with the statistical analysis plan (SAP).', 'Analysis of PFS for Futility or', 'Section 5.1.2 Secondary Objectives', 'Superiority', \"To compare the ORR ( PR) based on the IRC's\", 'Section 13.5.1.2: Primary', 'response outcome assessments (Section 6.4), in', 'Analysis for ORR (in v3) was', 'patients randomized to the SVd Arm versus the Vd', 'deleted', 'Arm', 'Section 13.5.2.1: Overall', 'To compare the incidence of any Grade >2', 'Response Rate (new)', 'peripheral neuropathy events (total Grade >2 and', 'Section 14.11: Study Report and', 'separately for Grades 2,3, and 4) in patients', 'Publication Policy', 'randomized to the SVd Arm versus patients', 'randomized to the Vd Arm', 'Section 5.2.1 Primary Enppoints', 'PFS, defined as time from date of randomization', 'until the first date of PD, per IMWG response', 'criteria, or death due to any cause, whichever', 'occurs first. For the purposes of PFS', 'determination, PD will be determined by the IRC.', 'ORR, defined as any response PR based on the', \"IRC's response outcome assessments, according\", 'to the IMWG response criteria. All changes in', 'MM disease assessments will be based on', 'bascline MM disease assessments from C1D1 of', 'study treatment.', 'Section 5.2.2.1 Key Secondary Efficacy Enppoints', 'ORR, defined as any response > PR (ie, PR, VGPR,', \"CR, or sCR) based on the IRC's response outcome\", 'assessments, according to the IMWG response criteria.', 'All changes in MM disease assessments will be based', 'on baseline MM disease assessments.', 'Confidential', 'Page 117', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Section(s)', 'Description of Change', 'Rationale for the Change', 'Response rates at any time prior to PD or death due to', 'any cause, pooled and separately for the following', 'responses: > VGPR, > CR, > sCR, or MRD negative', '(for patients who achieve CR or sCR)', '13.2.1.1 Interim Analysis of PFS for Sample Size', 'Re-estimation', 'CCI', 'Confidential', 'Page 118', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Section(s)', 'Description of Change', 'Rationale for the Change', 'CCI', 'Confidential', 'Page 119', 'Version 4.0']\n\n###\n\n", "completion": "END"}